2.58
price up icon2.79%   0.07
pre-market  시장 영업 전:  2.57   -0.01   -0.39%
loading
전일 마감가:
$2.51
열려 있는:
$2.55
하루 거래량:
2.06M
Relative Volume:
0.90
시가총액:
$868.34M
수익:
-
순이익/손실:
$-75.80M
주가수익비율:
-7.3714
EPS:
-0.35
순현금흐름:
$-68.07M
1주 성능:
-0.39%
1개월 성능:
-3.73%
6개월 성능:
-14.00%
1년 성능:
+76.71%
1일 변동 폭
Value
$2.50
$2.66
1주일 범위
Value
$2.47
$2.765
52주 변동 폭
Value
$1.44
$4.1598

Nuvation Bio Inc Stock (NUVB) Company Profile

Name
명칭
Nuvation Bio Inc
Name
전화
(415) 754-3517
Name
주소
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Name
직원
203
Name
트위터
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
NUVB's Discussions on Twitter

NUVB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NUVB
Nuvation Bio Inc
2.58 868.34M 0 -75.80M -68.07M -0.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-03-27 업그레이드 Jefferies Hold → Buy
2024-03-26 업그레이드 BTIG Research Neutral → Buy
2023-01-06 다운그레이드 Jefferies Buy → Hold
2022-08-02 다운그레이드 BMO Capital Markets Outperform → Market Perform
2022-08-02 다운그레이드 BTIG Research Buy → Neutral
2022-05-04 개시 H.C. Wainwright Buy
2021-10-15 재개 BTIG Research Buy
2021-04-06 개시 RBC Capital Mkts Outperform
2021-03-08 개시 BMO Capital Markets Outperform
2021-03-08 개시 BTIG Research Buy
2021-03-08 개시 Cowen Outperform
2021-03-08 개시 Jefferies Buy
2021-03-08 개시 Wedbush Outperform
모두보기

Nuvation Bio Inc 주식(NUVB)의 최신 뉴스

pulisher
Jan 17, 2025

Nuvation Bio Inc. (NYSE:NUVB) Short Interest Update - MarketBeat

Jan 17, 2025
pulisher
Jan 14, 2025

Nuvation Bio (NYSE:NUVB) Trading Down 5.6%Should You Sell? - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Jane Street Group LLC Decreases Stake in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

Nuvation Bio Inc. (NYSE:NUVB) Holdings Decreased by Jane Street Group LLC - MarketBeat

Jan 13, 2025
pulisher
Jan 10, 2025

HC Wainwright Predicts Stronger Earnings for Nuvation Bio - Defense World

Jan 10, 2025
pulisher
Jan 09, 2025

FY2024 EPS Estimate for Nuvation Bio Increased by Analyst - MarketBeat

Jan 09, 2025
pulisher
Jan 08, 2025

Nuvation Bio (NYSE:NUVB) Stock Price Down 8.3%Here's Why - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Canada

Jan 08, 2025
pulisher
Jan 08, 2025

Principal Financial Group Inc. Reduces Stock Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Jan 08, 2025
pulisher
Jan 07, 2025

Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

Nuvation Bio's (NUVB) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Nuvation Bio (NYSE:NUVB) Shares Gap UpHere's What Happened - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

FDA progress and strong trial data drive positive outlook for Nuvation Bio stock - Investing.com Australia

Jan 07, 2025
pulisher
Jan 07, 2025

Nuvation Bio (NYSE:NUVB) Given Buy Rating at HC Wainwright - Defense World

Jan 07, 2025
pulisher
Jan 07, 2025

Nuvation Bio’s (NUVB) “Outperform” Rating Reaffirmed at Wedbush - Defense World

Jan 07, 2025
pulisher
Jan 06, 2025

Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Lelezard

Jan 06, 2025
pulisher
Jan 06, 2025

Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer - BioSpace

Jan 06, 2025
pulisher
Jan 03, 2025

Innovent wins second China nod for Nuvation-partnered cancer therapy - MSN

Jan 03, 2025
pulisher
Jan 03, 2025

Nuvation Bio (NYSE:NUVB) Trading Up 10%Time to Buy? - MarketBeat

Jan 03, 2025
pulisher
Jan 03, 2025

Innovent wins China nod for Nuvation Bio drug (NUVB:NYSE) - Seeking Alpha

Jan 03, 2025
pulisher
Jan 02, 2025

Geode Capital Management LLC Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat

Jan 02, 2025
pulisher
Jan 02, 2025

Geode Capital Management LLC Boosts Holdings in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Jan 02, 2025
pulisher
Jan 01, 2025

Nuvation Bio Inc.'s (NYSE:NUVB) institutional investors lost 5.7% last week but have benefitted from longer-term gains - Simply Wall St

Jan 01, 2025
pulisher
Dec 30, 2024

Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now? - Insider Monkey

Dec 30, 2024
pulisher
Dec 27, 2024

FDA Accepts for Priority Review Nuvation Bio’s NDA for Taletrectinib to Treat Advanced ROS1-positive Non-Small Cell Lung Cancer - Specialty Pharmacy Continuum

Dec 27, 2024
pulisher
Dec 27, 2024

Nuvation Bio Inc. (NYSE:NUVB) Stock Position Raised by State Street Corp - Defense World

Dec 27, 2024
pulisher
Dec 27, 2024

Nuvation Bio Inc. (NYSE:NUVB) Stake Increased by State Street Corp - MarketBeat

Dec 27, 2024
pulisher
Dec 24, 2024

FDA sets review date for Nuvation Bio’s cancer drug By Investing.com - Investing.com Nigeria

Dec 24, 2024
pulisher
Dec 24, 2024

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio Inc.'s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer - Marketscreener.com

Dec 24, 2024
pulisher
Dec 24, 2024

Nuvation Bio’s (NUVB) Outperform Rating Reaffirmed at Wedbush - Defense World

Dec 24, 2024
pulisher
Dec 23, 2024

Wedbush Reaffirms "Outperform" Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat

Dec 23, 2024
pulisher
Dec 23, 2024

FDA sets review date for Nuvation Bio's cancer drug By Investing.com - Investing.com Australia

Dec 23, 2024
pulisher
Dec 23, 2024

FDA priority review for Nuvation Bio's taletrectinib - The Pharma Letter

Dec 23, 2024
pulisher
Dec 23, 2024

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer - BioSpace

Dec 23, 2024
pulisher
Dec 23, 2024

FDA sets review date for Nuvation Bio's cancer drug - Investing.com

Dec 23, 2024
pulisher
Dec 21, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 8,670 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Dec 21, 2024
pulisher
Dec 20, 2024

Wellington Management Group LLP Purchases 283,642 Shares of Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Nuvation Bio (NYSE:NUVB) Trading Up 5%Still a Buy? - MarketBeat

Dec 19, 2024
pulisher
Dec 18, 2024

Verition Fund Management LLC Sells 13,409 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Dec 18, 2024
pulisher
Dec 15, 2024

Charles Schwab Investment Management Inc. Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Dec 15, 2024
pulisher
Dec 13, 2024

Nuvation Bio's SWOT analysis: taletrectinib drives stock outlook amid pipeline shifts - Investing.com

Dec 13, 2024
pulisher
Dec 13, 2024

Clear Street sets Nuvation Bio at Buy with $5 target By Investing.com - Investing.com South Africa

Dec 13, 2024

Nuvation Bio Inc (NUVB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
자본화:     |  볼륨(24시간):